Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$1.46 USD
-0.19 (-11.52%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.50 +0.04 (2.74%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NMRA 1.46 -0.19(-11.52%)
Will NMRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NMRA
JNJ Halts Development of Depression Drug Over Efficacy Concerns
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neumora Stock Hits Record Low on Depression Drug Study Failure
Other News for NMRA
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Q2 2025 Neumora Therapeutics Inc Earnings Call Transcript
Neumora Therapeutics GAAP EPS of -$0.33
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c)